(b).
| Controls† | Antigens | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| β-actin | GAPDH | BCP-20 | END | G250 | HAGE | NY-ESO-1 | PASD1 | P68 RNA helicase | SSX2 | SSX2IP | SURVIVIN | Tyrosinase | WT1 | ||
| Patient samples | ALL001 | + | + | + | + | – | + | + | – | + | – | – | – | – | + |
| ALL002 | + | + | + | + | – | – | – | – | + | – | + | + | – | + | |
| ALL004 | + | + | – | + | – | – | + | – | + | – | + | – | + | – | |
| ALL005 | + | + | + | – | – | – | + | – | + | – | –/+ | + | – | + | |
| ALL006 | + | + | + | + | + | + | + | – | + | – | + | + | – | + | |
| ALL007 | + | + | – | + | – | – | + | – | + | – | + | – | – | + | |
| ALL008 | + | + | – | + | – | – | – | – | – | – | – | – | – | – | |
| ALL009BM | + | + | – | + | – | – | + | – | – | – | – | + | – | – | |
| ALL010BM | + | + | + | + | + | + | + | – | + | – | + | + | + | – | |
| ALL010PB | + | + | + | + | – | – | + | – | + | – | + | + | – | – | |
| ALL012BM | + | + | + | + | – | + | – | + | – | + | + | + | – | ||
| ALL012PB | + | + | – | + | – | + | + | – | + | – | + | + | – | – | |
| ALL013BM | + | + | – | + | + | – | + | – | – | – | + | + | – | + | |
| Total‡ | 11/11 | 11/11 | 6/11 | 10/11 | 3/11 | 4/11 | 9/11 | 0/11 | 9/11 | 0/11 | 8/11 | 7/11 | 3/11 | 5/11 | |
| HV samples (all PB) | HV003 | + | + | + | – | –/+ | + | + | – | + | – | + | – | + | – |
| HV004 | + | + | – | – | – | – | – | – | – | – | – | – | |||
| HV006 | + | + | – | – | + | – | + | – | + | – | + | – | – | – | |
| HV007 | + | + | – | – | – | – | – | – | – | – | – | – | – | – | |
| HV016 | + | + | – | – | – | – | – | – | – | – | – | – | – | – | |
| HV021 | + | + | + | – | –+ | + | + | – | + | – | + | – | + | – | |
| HV032 | + | + | – | – | – | – | – | – | – | – | – | – | – | – | |
| HV033 | + | + | – | – | – | – | – | – | – | – | – | – | – | – | |
| Total | 8/8 | 8/8 | 2/8 | 0/8 | 3/8 | 2/8 | 3/8 | 0/8 | 3/8 | 0/8 | 3/8 | 0/8 | 3/8 | 0/8 | |
BM: bone marrow; HV: healthy volunteer; PB: peripheral blood. †: controls for the integrity of the cDNA samples for PCR amplification; ‡number of patients with antigen positive samples (n = 11) encompassing the analysis of 13 samples.